Skip to content
Open access · CC-BY via OpenAlex

Synergistic senolytic–regenerative therapy significantly extends healthspan and lifespan

Thomas E. Ichim, Nikola Markov, Gilberto Lopes, Karenjan A. Pascual, Anastasiia Evans, Robert S. Reznik, Vladyslav Bykoriz, Christian A. Fortunati, Boris Minev, Roman A. Ramos, Anil Bajnath, Emma Lin, JOYCE HU, Francesco Maria Marincola, Armin V. Rath

Journal of Translational Medicine · 2026 · ▲ 4 citations

Abstract

BACKGROUND: Current barriers to achieving radical life extension include the inability to use syngeneic, youthful mesenchymal stem cells (MSCs) and the anti-regenerative effects of senescence(definition)-associated secretory phenotype (SASP) factors. We aim to overcome this by a combination approach in which senescent cell burden is reduced utilizing SenoVax™ a dendritic cell based senolytic immunotherapy combined with syngeneic pluripotent stem cell derived MSC. METHODS: We induced hepatic injury and accelerated aging using two established murine models: carbon tetrachloride (CCl₄) mediated liver injury and doxorubicin induced systemic senescence. Animals were treated with control, SenoVax, pMSCs or the combination. Outcomes included biochemical and histologic indices of liver injury, circulating and tissue biomarkers of senescence (IL-11, YKL-40, IL-6, IL-23 R) and regeneration (Klotho, FGF-2, neo-VEGF, GDF-11), RESULTS: Both CCl₄ and doxorubicin induced a robust senescent phenotype characterized by increased pro-inflammatory and pro-fibrotic mediators and downregulation of regenerative biomarkers. Combined senolytic and pMSC therapy outperformed mono therapies and produced clear synergistic benefits, including significant biochemical improvement of liver failure parameters, reversal of accelerated aging features, and restoration of regenerative signaling pathways. Senolytic monotherapy yielded partial improvements, while pMSCs alone showed limited activity in the presence of a high senescent-cell burden. CONCLUSIONS: These findings support a mechanistic model in which senescent cells and SASP factors directly suppress MSC-mediated tissue repair. Targeted senolytic immunotherapy enhances the efficacy of regenerative interventions and represents a promising combinatorial strategy for chronic disease management and potentially for modifying biological aging itself. CLINICAL TRIAL NUMBER: Not applicable.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1186/s12967-026-08221-y
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Ichim, T.E., Markov, N., Lopes, G., Pascual, K.A., Evans, A., Reznik, R.S., Bykoriz, V., Fortunati, C.A., Minev, B., Ramos, R.A., Bajnath, A., Lin, E., HU, J., Marincola, F.M., Rath, A.V., Barrett, B., Jurow, A., Sankhala, K.K., Furman, D., &amp; Reznik, B.N. (2026). Synergistic senolytic–regenerative therapy significantly extends healthspan and lifespan. <em>Journal of Translational Medicine</em>. https://doi.org/10.1186/s12967-026-08221-y
Vancouver
Ichim TE, Markov N, Lopes G, Pascual KA, Evans A, Reznik RS, et al. Synergistic senolytic–regenerative therapy significantly extends healthspan and lifespan. Journal of Translational Medicine. 2026. doi:10.1186/s12967-026-08221-y.
BibTeX
@article{thomas2026Synerg, title = {Synergistic senolytic–regenerative therapy significantly extends healthspan and lifespan}, author = {Thomas E. Ichim and Nikola Markov and Gilberto Lopes and Karenjan A. Pascual and Anastasiia Evans and Robert S. Reznik and Vladyslav Bykoriz and Christian A. Fortunati and Boris Minev and Roman A. Ramos and Anil Bajnath and Emma Lin and JOYCE HU and Francesco Maria Marincola and Armin V. Rath and Barbie Barrett and Andrew Jurow and Kamlesh Kumar Sankhala and David Furman and Boris N Reznik}, journal = {Journal of Translational Medicine}, year = {2026}, doi = {10.1186/s12967-026-08221-y}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings